NovaBay Pharmaceuticals, Inc. (NBY)

1.96 0.01 (0.51%)

As of 2026-04-02 18:54:53 EST

NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis

Traded asNYSE: NBY
ISINUS66987P5089
CIK0001389545
LEI549300D5U7PQPNEX8Q38
EIN680454536
Sector—
IndustryPharmaceutical Preparations
CEO—
Employees—
Fiscal Year End1231
Address2000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608
Phone(510) 899-8800
Websitehttp://novabay.com
Stock Quotes
trading_symbolregistrant_nametimepricechangepercentage_change
NBYNovaBay Pharmaceuticals, Inc.2026-04-02 18:54:531.960.010.51
This is a preview of the latest data. Subscribe to access the full data.
Company Information
trading_symbolcentral_index_keyregistrant_nameisin_numberlei_numberein_numberexchangesic_codesic_descriptionfiscal_year_endstate_of_incorporationaddress_streetaddress_cityaddress_stateaddress_zip_codeaddress_countryaddress_country_codephone_numbermailing_addressbusiness_addressformer_nameindustryfounding_datechief_executive_officernumber_of_employeeswebsitemarket_capshares_issuedshares_outstandingdescriptionupdate_time
NBY0001389545NovaBay Pharmaceuticals, Inc.US66987P5089549300D5U7PQPNEX8Q38680454536NYSE2834Pharmaceutical Preparations1231DE2000 POWELL STREET, SUITE 1150EMERYVILLECA94608UNITED STATESUS(510) 899-88002000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 946082000 POWELL STREET, SUITE 1150, EMERYVILLE, CA, 94608NovaBay Pharmaceuticals, Inc.—2000——http://novabay.com3,373,12625,216,00026,625,029NovaBay Pharmaceuticals, Inc. is an Emeryville, California based clinical-stage biopharmaceutical company, focused on products for eye care. Major products include Avenova, cleared by FDA for lid and lash cleansing as part of a regimen for Blepharitis. and NeutroPhase, used in treatment of Necrotizing Fasciitis2026-04-02 19:52:09
This is a preview of the latest data. Subscribe to access the full data.
NBY Stock Price (End-of-Day)
This is a preview of the latest data. Subscribe to access the full data.
NBY Stock Price (1-Minute)
This is a preview of the latest data. Subscribe to access the full data.
Market Cap
Fiscal YearMarket CapChange In Market CapPercentage Change In Market CapShares OutstandingChange In Shares OutstandingPercentage Change In Shares Outstanding
20253,373,126394,01913.226126,625,02920,808,825357.7733
20242,979,107-71,378-2.33995,816,204-24,281,946-80.6759
20233,050,485-7,825,013-71.950830,098,15027,903,7061,271.5615
This is a preview of the latest data. Subscribe to access the full data.
Executive Compensation
Executive NameExecutive PositionFiscal YearSalaryBonusStock AwardsIncentive Plan CompensationOther CompensationTotal Compensation
Justin M. HallVP, CEO, Chief Compliance Officer2024350,0000——15,177365,177
Tommy LawTreasurer, CFO2024170,00042,500——7,696220,196
Andrew JonesChief Financial Officer202377,88300—139,078216,961
Audrey KuninChief Product Officer2023170,51300—5,000175,513
Justin M. HallVP, CEO, Chief Compliance Officer2023350,0000——14,146364,146
This is a preview of the latest data. Subscribe to access the full data.
Employee Count
Fiscal YearEmployee Count
20254
202414
202326
This is a preview of the latest data. Subscribe to access the full data.
Income Statements
Fiscal Year202520242023
Revenue—9,781,00014,726,000
Cost Of Revenue—3,300,0006,831,000
Gross Profit—6,481,0007,895,000
Research And Development Expenses—42,00068,000
General And Administrative Expenses7,585,0007,379,0006,330,000
Operating Expenses8,439,00012,320,00015,491,000
Operating Income-8,439,000-5,839,000-7,596,000
Net Income-22,141,000-7,223,000-9,640,000
Earnings Per Share Basic-3.8-2.53-3.96
Earnings Per Share Diluted———
Weighted Average Shares Outstanding Basic5,820,0003,396,0004,215,000
Weighted Average Shares Outstanding Diluted———
This is a preview of the latest data. Subscribe to access the full data.
Balance Sheet Statements
Fiscal Year202520242023
Cash And Cash Equivalents7,958,000430,0003,130,000
Marketable Securities Current———
Accounts Receivable—194759,000
Inventories—765,0002,877,000
Non Trade Receivables———
Other Assets Current177,000110,00081,000
Total Assets Current8,675,0001,935,0007,154,000
Marketable Securities Non Current———
Property Plant And Equipment—53,00087,000
Other Assets Non Current360,000480,000497,000
Total Assets Non Current360,0001,488,0001,880,000
Total Assets9,035,0003,423,0009,034,000
Accounts Payable257,000623,0001,130,000
Deferred Revenue———
Short Term Debt——1,831,000
Other Liabilities Current396,0001,257,0001,516,000
Total Liabilities Current1,142,0002,843,0004,278,000
Long Term Debt———
Other Liabilities Non Current———
Total Liabilities Non Current30,719,000709,0001,442,000
Total Liabilities31,861,0003,552,0005,720,000
Common Stock252,00049,000112,000
Retained Earnings-210,415,000-183,457,000-174,849,000
Accumulated Other Comprehensive Income———
Total Shareholders Equity-23,176,000-129,0003,314,000
This is a preview of the latest data. Subscribe to access the full data.
Cash Flow Statements
Fiscal Year202520242023
Depreciation And Amortization—40,00051,000
Share Based Compensation Expense———
Other Non Cash Income Expense———
Change In Accounts Receivable89,000-291,000-1,214,000
Change In Inventories-73,000272,000-560,000
Change In Non Trade Receivables———
Change In Other Assets85,0002,00017,000
Change In Accounts Payable-37,000-195,000-1,158,000
Change In Other Liabilities———
Cash From Operating Activities-8,430,000-5,183,000-4,131,000
Purchases Of Marketable Securities———
Sales Of Marketable Securities———
Acquisition Of Property Plant And Equipment—6,00019,000
Acquisition Of Business———
Other Investing Activities———
Cash From Investing Activities11,000,0001,064,000-19,000
Tax Withholding For Share Based Compensation———
Payments Of Dividends4,817,000——
Issuance Of Common Stock———
Repurchase Of Common Stock175,000——
Issuance Of Long Term Debt———
Repayment Of Long Term Debt———
Other Financing Activities———
Cash From Financing Activities4,615,0001,500,0001,910,000
Change In Cash7,318,000-2,699,000-2,240,000
Cash At End Of Period7,958,000430,0003,130,000
Income Taxes Paid——359,000
Interest Paid8,000147,000326,000
This is a preview of the latest data. Subscribe to access the full data.
Key Metrics
Fiscal Year202520242023
Earnings Per Share-3.8-2.53-3.96
Price To Earnings Ratio-7.4211-1.1877-9.0156
Earnings Growth Rate50.1976-36.1111-60.7921
Price Earnings To Growth Ratio-0.14780.03290.1483
Book Value Per Share-3.922-0.0380.7862
Price To Book Ratio-7.1902-79.108445.4083
Ebitda—-7,183,000-9,230,000
Enterprise Value———
Dividend Yield0.0293——
Dividend Payout Ratio-0.2176——
Debt To Equity Ratio———
Capital Expenditures—6,00019,000
Free Cash Flow—-5,189,000-4,150,000
Return On Equity0.955355.9922-2.9089
One Year Beta0.55890.12220.73
Three Year Beta0.49240.54070.6308
Five Year Beta0.56190.51260.792
This is a preview of the latest data. Subscribe to access the full data.
Insider Transactions
Insider NameRelationship To IssuerTransaction DateAmount Of SecuritiesAcquired Or DisposedSecurities Owned Following Transaction
Sit SwanDirector2026-03-31140,000A140,000
Kazley Michael JohnDirector, Chief Executive Officer, 10% owner2026-03-314,118,828A4,118,828
Kazley Michael JohnDirector, Chief Executive Officer, 10% owner2026-03-317,722,802A7,722,802
Kazley Michael JohnDirector, Chief Executive Officer, 10% owner2025-10-2156,806,080A56,806,080
R01 Fund LPDirector, Chief Executive Officer, 10% owner2025-10-2156,806,080A56,806,080
This is a preview of the latest data. Subscribe to access the full data.
Institutional Holdings
Investor NamePeriod Of ReportMarket ValueAmount Of SecuritiesPrice Per Security
GOLDMAN SACHS GROUP INC2025-12-31588,483104,3415.64
Compound Planning, Inc.2025-12-3194,87016,8215.64
BANK OF AMERICA CORP /DE/2025-12-316,7511,1975.6399
Qube Research & Technologies Ltd2025-12-31230,25940,8265.64
NORTHERN TRUST CORP2025-12-311,544,164273,7885.64
This is a preview of the latest data. Subscribe to access the full data.
Mutual Fund Holdings
Registrant NamePeriod Of ReportFund NameFund SymbolAmount Of UnitsValue In UsdPercentage Value Compared To Assets
FIDELITY CONCORD STREET TRUST2025-11-30Fidelity Total Market Index FundFSKAX16,19417,651.460.0
FIDELITY CONCORD STREET TRUST2025-11-30Fidelity Series Total Market Index FundFCFMX7,7838,483.470.0
FIDELITY CONCORD STREET TRUST2025-11-30Fidelity Extended Market Index FundFSMAX27,18029,626.20.0001
VANGUARD INDEX FUNDS2025-09-30Institutional Select SharesVSEMX59,24175,828.480.0001
VANGUARD INDEX FUNDS2025-09-30Institutional Plus SharesVEMPX59,24175,828.480.0001
This is a preview of the latest data. Subscribe to access the full data.